Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs.

Baniel, J; Israilov, S; Engelstein, D; Shmueli, J; Segenreich, E; Livne, P M

Baniel, J; Israilov, S; Engelstein, D; Shmueli, J; Segenreich, E; Livne, P M.

Affiliation

Baniel J; Institute of Urology, Rabin Medical Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Urology ; 56(4): 647-52, 2000 Oct 01.

Article in En | MEDLINE | ID: mdl-11018623

Subject(s)

Alprostadil/administration & dosage; Erectile Dysfunction/drug therapy; Papaverine/administration & dosage; Phentolamine/administration & dosage; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage/chemically induced; Humans; Male; Middle Aged; Pain/chemically induced; Priapism/chemically induced; Treatment Outcome

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Papaverine / Phentolamine / Alprostadil / Erectile Dysfunction Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Year: 2000 Type: Article

Search on Google

XML

PubMed Links